Didactic Series. Non-Infectious Complications of HIV. Ankita Kadakia, MD UC San Diego, Owen Clinic November 8, 2018

Size: px
Start display at page:

Download "Didactic Series. Non-Infectious Complications of HIV. Ankita Kadakia, MD UC San Diego, Owen Clinic November 8, 2018"

Transcription

1 Didactic Series Non-Infectious Complications of HIV Ankita Kadakia, MD UC San Diego, Owen Clinic November 8,

2 Disclosures The following presenter have disclosed the following relationship with a commercial interest. Ankita Kadakia,MD Type of relationship: Spouse, Proteus Digital Resolution: This presentation has been reviewed by the PAETC Clinical Director, who reports the above disclosures have had no affect on the content of this presentation. All other presenters of this continuing medical education activity have indicated that neither they nor their spouse/legally recognized domestic partner has any financial relationships with commercial interests related to the content of this activity. 2

3 Learning Objectives 1) To understand how HIV/AIDS affects multiple organ systems and the related noninfectious complications 2) To understand how the use of ART affects multiple organ systems and related noninfectious complications 3) To understand the role of HIV/AIDS in the aging process 3

4 Poll Question Which of the following are risk factors for osteoporosis in PLWHIV? A. Smoking B. HIV C. Hypogonadism D. Low BMI E. Only A and D F. All of the above 4

5 2489 patient with HIV followed for 3 years for hip fracture vs noninfected cohort When traditional risk factors of smoking, low BMI, age, gender, glucocorticoid use, hypogonadism, comorbid conditions were adjusted for they showed that HIV was independently was higher risk than non-hiv patients May be related to proinflammatory affects of HIV and side effects of ART 5

6 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system

7 Effective Treatment Saves Lives 7

8 HIV and Aging PLWHIV are living longer and now seeing diseases of older age which was not previously seen before due to the success of cart PLWHIV who take ART are more likely to die of noninfectious complications vs infectious complications of HIV HIV can accelerate noninfectious diseases such as CV events since HIV acts as a proinflammatory state What are PLWHIV on successful ART dying from? Frailty Cardiovascular events- MI/CVA Diabetes related complications Malignancies

9 Analysis of longitudinal data from Modena HIV Metabolic Clinic (MHMC) cohort study in Modena, Italy Measuring frailty as a predictor of mortality using a frailty index score in 963 participants Frailty index scores at baseline and either died or were followed for four years

10 Frailty Index Frailty index score is calculated as the proportion of health deficits present out of all health variables considered Health variables can include CKD, osteoporosis, hypercholesterolemia, proteinuria and many others CD4 nadir, years of ART, age at diagnosis, co-morbidities, viral hepatitis Greater the frailty index score the higher the mortality rate

11 Female sex, higher current and nadir CD4 cell counts, and fewer smoking pack years had lower frailty index scores indicating lower mortality rates Frailty index scores can change over time with modifiable risks such as smoking How well someone with HIV ages depends on how frail they are

12 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system

13

14

15

16 Increased prevalence of smoking 2-3 times higher than general population in PLWHIV Increase due to low socioeconomic and educational levels, psychiatric comorbidity, concurrent illicit drug and alcohol use, and mental stress which are all higher in PLWHIV Current smokers had a significantly higher risk for all-cause mortality than former smokers and never smokers when controlling for age, race, sex, CD4 count, viral load COPD is more common and emphysema is accelerated in HIV-infected patients Other diseases such as periodontal disease, osteoporosis, HPV oral cancer and anal cancer increased with HIV + smoking than HIV alone or general population HIV/AIDS CID 2013:57 (15 July) 275

17

18 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system

19 Bone Loss and HIV Bone loss may occur not only due to HIV/AIDS but also as a consequence of HAART Estimated that 15% of PLWHIV develop osteoporosis and 52% osteopenia Protease inhibitors and TDF are highest amongst ART regimens for causing osteoporosis Bone loss is multifactorial- unclear if direct effect of HIV or as a consequence of traditional osteoporosis risk factors associated with patient lifestyle (smoking and alcohol consumption) Other AIDS-associated diseases like muscle wasting, kidney disease, and hypogonadism, low vitamin D levels increase bone loss Curr Opin Endocrinol Diabetes Obes Dec; 17(6):

20 Meta-analysis of 20 studies conducted Jan Nov 2005 Compared HIV-positive vs HIV-negative; ART-treated vs ART-naive;protease inhibitor (PI)- treated vs PI-untreated Of the 884 HIV-infected patients, 67% had reduced BMD, of whom 15% had osteoporosis compared with HIV-uninfected controls (n.654) using 11 studies with available data. Compared with ART-naive patients (n.202, 10 studies),art-treated individuals (n.824) had a 2.5-fold increased odds of prevalent reduced BMD. The risk of prevalent osteoporosis (seven studies) was similarly elevated in ARTtreated individuals. Compared with non-pi-treated HIV patients (n.410, 14 studies),pi-treated patients (n.791) had increased odds of reduced BMD and osteoporosis (12 studies) Prevalence of osteoporosis in HIV-infected individuals is more than three times greater compared with HIV-uninfected controls. ART-exposed and PI exposed individuals had a higher prevalence of reduced BMD and osteoporosis compared with their respective controls CIDS 2006, 20:

21 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system

22 Poll Question Distal sensory polyneuropathy is the most common form of HIV associated neuropathy. Which of the following are risk factors for the development of neuropathy in PLWHIV? A. Low CD4 count B. Longer duration of untreated HIV C. High viral load D. Older age E. A, B, and C F. All of the above 22

23 HIV associated Neuropathy MC pain syndrome ~ 33% of PLWHIV affected Can occur as a complication of HIV/AIDS or related to ART NRTIs most common ART, incidence of neuropathy is related to the degree of mitrochondrial toxicity with certain nucleoside reverse transcriptase inhibitors (NRTIs) Didanosine and stavudine inhibit mitochondrial DNA synthesis more tightly than zidovudine, lamivudine Hypothesized that the HIV-1 envelope protein (gp120) may cause neuronal injury indirectly through Schwann cells by inducing upregulation of TNF-alpha, which may result in apoptotic death of sensory neurons

24

25

26 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system

27 Grand Rounds Michael Rubin, MD Department of Ophthalmology and Visual Science The University of Chicago HIV Retinopathy Most common retinal pathology in HIV, occurs in as many as 50-70% of PLWHIV Often manifests as cotton-wool spots Etiology is increased plasma viscosity, immune-complex deposition, and a direct cytopathic effect of HIV on the retinal vascular endothelium The arteriolar occlusion in HIV microvasculopathy leads to interruption of the axoplasmic flow, which manifests as cotton-wool spots No treatment except ART

28

29 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system

30 Noninfectious Pulmonary HIV Malignancy Inflammatory Pulmonary Vasculature AIDS Defining Non-AIDs Defining LIP NSIP Pulmonary HTN

31 Lung Malignancy AIDS-Defining HHV-8, EBV Kaposi s sarcoma Primary effusion lymphoma Non-Hodgkin s Lymphoma Am J Med Sci Dec;348(6):502-11

32 Lung Malignancy Non-AIDS Defining Higher incidence than general population even with ART use Unclear etiology but increased tobacco use and level of immunosuppression related Occur at younger age, ~48 compared with gen population ~60, more aggressive advanced forms Adenocarcinoma is MC form Screening is similar to general population 32

33 Inflammatory Lymphocyte Interstitial Pneumonia- influx of lymphocytes into alveolar space, includes NSIP HIV-related proteins in germinal centers, pulmonary interstitium and BAL as likely a direct cause of HIV May be related to immune reconstitution inflammatory syndrome

34 Pulmonary Vasculature Pulmonary HTN Incidence estimated at 0.5% which represents relative risk of 1000 fold compared with general population Worse prognosis for PLWHIV + PH compared to PLWHIV alone Inflammation, genetics, intravenous drug use, coinfections and viral proteins may contribute Gp120 has been shown to target pulmonary endothelial cells and increase secretion of endothelin-1, a potent vasoconstrictor

35 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system

36 Noninfectious Gastrointestinal HIV Complications Nausea and Vomiting 2/2 to ART Chronic diarrhea 2/2 HIV enteropathy Pancreatitis 2/2 ART stavudine, didanosine, NRTIs, dolutegravir

37 HIV Enteropathy Chronic, well-established diarrhea (> 1 month duration) with no identified infectious cause after thorough evaluation Related to direct or indirect effects of HIV on the enteric mucosa a diagnosis of exclusion made after other forms of diarrheal illness have been ruled out Diarrhea 2/2 to ART : PI > NRTI> NNRTI > INSTI Gut-associated lymphoid tissue (GALT) is the largest collection of lymphoid tissue in the human body Persistent stimulation of the immune system by HIV in the gut Baseline inflammatory state that encourages the production of proinflammatory chemokines which mediate the movement of lymphocytes into the mucosal tissues, damage to gut epithelial cells ( gp 120), depletion of gut CD4 cells but increased CD8 cell that are primed to produce cytokines which may damage the mucosal barrier Even after starting ART, diarrhea can persists due to the damage of gut mucosa by HIV Dig Dis Sci. 2015; 60(8):

38

39

40 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system

41 Poll Question 60 Y AA M with CD4 20, VL 1mil, new dx, presents on initial visit with flank pain. You obtain an UA which shows 3+ proteinuria and Cr 4.0, no baseline to compare. What should you do next? A. Obtain a renal biopsy to confirm FSGS B. Start ART immediately C. Obtain a renal US D. A and C 41

42 HIV Associated Nephropathy (HIVAN) Complication of untreated advanced HIV/AIDS Most predominant in African Americans with 90% of cases Rapidly progressive renal failure Moderate to nephrotic range proteinuria Bland urinary sediment Ultrasound findings of large, highly echogenic kidneys HIVAN is a collapsing glomerulopathy of focal segmental glomerulosclerosis (FSGS)

43 HIVAN Pathogenesis of HIVAN requires local HIV infection of the kidney, with the virus infecting tubular and glomerular epithelial cells ART is effective at preventing and reversing HIVAN hence should be started immediately even without a genotype HIVAN has become less prevalent with ART use

44 Semin Nephrol Nov; 28(6):

45 Tenofovir related Fanconi Syndrome Tenofovir disoproxil fumarate affects the proximal renal tubule Glucosuria, proteinuria, elevated urine potassium Hypokalemia, hypophophatemia, metabolic acidosis TDF has higher circulating plasma levels leading to more renal and bone disease vs TAF which goes directly to tissue causing lower plasma concentrations

46 HIV affects every organ Cardiovascular Bone Dermatologic Neurologic Ocular Pulmonary GI tract Renal Endocrine system

47 Hypogonadism Occurs more frequently in poorly controlled or uncontrolled HIV/AIDS but prevalence is decreasing with ART Measured by morning (before 10am) total testosterone Male hypogonadism can lead to osteoporosis, erectile dysfunction/decreased libido, reduced lean body mass/muscle strength, depression, and the metabolic syndrome Used to be more frequent among men with the AIDS and was attributed to testicular dysfunction due to opportunistic infections, cancers, wasting syndrome, and cytokine disorders With ART use, now found to be related to hypothalamicpituitary axis impairment, aging,and comorbidities (alcoholism, hepatitis C, and injecting drug use) AIDS: January 28th, Volume 31 - Issue 3 - p

48 Prospective observational study of 33,389 HIV-infected patients; diabetes is a study end point 744 patients or incidence rate of 5.72 per 1,000 person year follow up The incidence of diabetes increased with cumulative exposure to cart, an association that remained significant after adjustment for potential risk factors for diabetes NRTIs and Protease Inhibitors cause insulin resistance leading to increased blood glucose levels and Type 2 diabetes Do not need to stop or change ART, lifestyle modification followed by diabetes medication Consider avoiding PI if a patient already has diabetes prior to HIV diagnosis

49 Thank you! 49

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. HIV and the Kidney. Leah Haseley, MD. Presentation prepared by: LH NW AETC ECHO June 2012

NORTHWEST AIDS EDUCATION AND TRAINING CENTER. HIV and the Kidney. Leah Haseley, MD. Presentation prepared by: LH NW AETC ECHO June 2012 NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and the Kidney Leah Haseley, MD Presentation prepared by: LH NW AETC ECHO June 2012 Etiology of renal disease in HIV 1985- The virus 1995- The antivirals

More information

Special Challenges and Co-Morbidities

Special Challenges and Co-Morbidities Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine

More information

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none

More information

No Conflict of Interest

No Conflict of Interest No Conflict of Interest Aging and HIV Co-Morbidities: A Challenge for Engagement in Care Maria L Alcaide M.D. Division of Infectious Diseases University of Miami Miller School of Medicine Objectives Understand

More information

C E L I A J. M A X W E L L, M. D

C E L I A J. M A X W E L L, M. D H I V / A I D S I N O L D E R I N D I V I D U A L S T H E G R A Y I N G O F T H E D I S E A S E E X T E N U A T I N G V S M I T I G A T I N G F A C T O R S C E L I A J. M A X W E L L, M. D., F A C P A

More information

HIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER

HIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER HIV ASSOCIATED NEPHROPATHIES (HIVAN): 30 YEARS LATER Gaston Zilleruelo M.D. Professor of Pediatrics Director of Pediatric Nephrology University of Miami/Holtz Children s Hospital Worldwide 33.2 million

More information

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,

More information

HIV and Common Comorbidities August 17, Michael MacVeigh, MD & Kristen Meyers, BS, CADC1

HIV and Common Comorbidities August 17, Michael MacVeigh, MD & Kristen Meyers, BS, CADC1 HIV and Common Comorbidities August 17, 2017 Michael MacVeigh, MD & Kristen Meyers, BS, CADC1 Learning Objectives 1) Confidently discuss basics of ARVs and common side effects of these medications 2) Understand

More information

HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD

HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD HIV and Bone Disease: Through Thick and Thin! Pablo Tebas, MD April 30 th, 2016 Disclosures I serve in an adjudication panel in a VZV vaccine study (Glaxo) I consult for Merck My research is supported

More information

PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV

PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV PROVIDING EXCELLENT PRIMARY CARE FOR PATIENTS LIVING WITH HIV Madhuri Lad, DO, FACOI, AAHIVS Clinical Assistant Professor OSU Department of Internal Medicine OBJECTIVES Demographics Definitions Diagnosis

More information

Dr Michael Rayment Chelsea and Westminster Hospital, London

Dr Michael Rayment Chelsea and Westminster Hospital, London 17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Dr Michael Rayment Chelsea and Westminster Hospital, London 6-8 April 2011, Bournemouth International Centre A decade of renal biopsies in

More information

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist

PAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical

More information

Aging and Cancer in HIV

Aging and Cancer in HIV Aging and Cancer in HIV Ronald Mitsuyasu, MD Professor of Medicine Director, UCLA Center for Clinical AIDS Research and Education Group Chairman, AIDS Malignancy Consortium (AMC) Age distribution of HIV-infected

More information

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body

HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University

More information

Comorbidities: a moving area. Paul De Munter ARC Leuven BREACH

Comorbidities: a moving area. Paul De Munter ARC Leuven BREACH Comorbidities: a moving area Paul De Munter ARC Leuven BREACH 27-11-2015 Contents Introduction Comorbidities Cardiovascular disease and lipids Diabetes mellitus Hepatitis C Frailty Conclusion Introduction

More information

HIV long term complications

HIV long term complications HIV- 2015 long term complications 4th Asian Conference on Hepatitis & AIDS 22-23 May 2015, Xi'an, China Kees Brinkman Amsterdam The Netherlands NL 2012: known 17.000 (0,1%) treatment 85% (all) China 2011:

More information

CLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to:

CLINICAL PEARLS OF NEW HIV MEDICATIONS PHARMACIST OBJECTIVES TECHNICIAN OBJECTIVES. At the end of this presentation pharmacists will be able to: CLINICAL PEARLS OF NEW HIV MEDICATIONS Cindy Lou Zoellner, PharmD, BCPS Added Qualifications in Infectious Diseases Senior Clinical Pharmacy Specialist in HIV Parkland Health & Hospital System Volunteer

More information

Hans Strijdom SA Heart Meeting November 2017

Hans Strijdom SA Heart Meeting November 2017 Hans Strijdom SA Heart Meeting November 2017 HIV-infection and ART, but not high sensitivity CRP, are associated with markers of vascular function: Results from the Western Cape cohort of the EndoAfrica

More information

COMPETING INTEREST OF FINANCIAL VALUE

COMPETING INTEREST OF FINANCIAL VALUE BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Dr Ian Williams University College London Medical School COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Ian Williams

More information

Case # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings

Case # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings Case # 2 Christopher Larsen, MD Arkana Laboratories Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content

More information

Update on HIV-Related Kidney Diseases. Agenda

Update on HIV-Related Kidney Diseases. Agenda Update on HIV-Related Kidney Diseases ANDY CHOI THE MEDICAL MANAGEMENT OF HIV/AIDS DECEMBER 15, 2006 Agenda 1. EPIDEMIOLOGY: A) END STAGE RENAL DISEASE (ESRD) B) CHRONIC KIDNEY DISEASE (CKD) 2. HIV-ASSOCIATED

More information

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University

HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start

More information

Didactic Series. Bone Health in the context of HIV. Christian B. Ramers, MD, MPH, AAHIVS Family Health Centers of San Diego 9/22/16

Didactic Series. Bone Health in the context of HIV. Christian B. Ramers, MD, MPH, AAHIVS Family Health Centers of San Diego 9/22/16 Didactic Series Bone Health in the context of HIV Christian B. Ramers, MD, MPH, AAHIVS Family Health Centers of San Diego 9/22/16 This project is supported by the Health Resources and Services Administration

More information

Increased and accelerated age-related complications in HIV-infected patients

Increased and accelerated age-related complications in HIV-infected patients Increased and accelerated age-related complications in HIV-infected patients Giovanni Guaraldi Università di Modena THE CHANGING SPECTRUM OF HIV CARE Pre- HAART 1996 Early- HAART 2005 Late- HAART Opportunistic

More information

Introduction to HIV and Aging

Introduction to HIV and Aging Introduction to HIV and Aging Sheree Starrett MD Medical Director - Rivington House June 27, 2008 Rivington House Objectives Know the demographics of aging and HIV Identify the similarities between aging

More information

TDF Renal Dysfunction

TDF Renal Dysfunction TDF Renal Dysfunction Sarala Naicker MBChB, FRCP, PhD Division of Nephrology Dept of Internal Medicine University of the Witwatersrand Johannesburg South Africa SA HIV Clinician Society Conference Cape

More information

HIV and your Bones Osteopenia and Osteoporosis

HIV and your Bones Osteopenia and Osteoporosis Osteopenia and Osteoporosis Background information For reasons not yet fully understood, higher rates of bone disease are starting to be seen in people living with HIV. These bone diseases include osteopenia

More information

Primary Care for Persons Living with HIV

Primary Care for Persons Living with HIV Primary Care for Persons Living with HIV Brian Montague, DO MS MPH Assistant Professor of Medicine Division of Infectious Diseases Warren Alpert School of Medicine Brown University Outline What constitutes

More information

Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006

Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006 13th Conference on Retroviruses and Opportunistic Infections Denver, CO, USA. February 5-9, 2006 Poster Number 777 Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir

More information

HIV IN OKLAHOMA MAKING A DIFFERENCE

HIV IN OKLAHOMA MAKING A DIFFERENCE HIV IN OKLAHOMA MAKING A DIFFERENCE Madhuri Lad, DO, FACOI, AAHIVS Assistant Program and Medical Director OSU Internal Medicine Specialty Services HIV Program Clinical Assistant Professor Rashes Demographics

More information

Prevalence of Comorbidities among HIV-positive patients in Taiwan

Prevalence of Comorbidities among HIV-positive patients in Taiwan Prevalence of Comorbidities among HIV-positive patients in Taiwan Chien-Ching Hung, MD, PhD Department of Internal Medicine National Taiwan University Hospital, Taipei, Taiwan % of participants Comorbidity

More information

PIs are the real world answer for the chronic patient s management. Giovanni Guaraldi

PIs are the real world answer for the chronic patient s management. Giovanni Guaraldi PIs are the real world answer for the chronic patient s management Giovanni Guaraldi HIV MEDICATION TOXICITY Ageing with HIV: The clinical consequences AGEING Heart disease Kidney disease Liver disease

More information

Continuing Education for Pharmacy Technicians

Continuing Education for Pharmacy Technicians Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected

More information

HIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School

HIV Infection as a Chronic Disease. Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School HIV Infection as a Chronic Disease Howard Libman, MD Beth Israel Deaconess Medical Center Harvard Medical School Role of Primary Care Approximately 50,000 patients are diagnosed with HIV infection annually

More information

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort

Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort Chua et al. AIDS Research and Therapy 2012, 9:19 SHORT REPORT Open Access Renal safety of tenofovir containing antiretroviral regimen in a Singapore cohort Arlene C Chua 1*, Ryan M Llorin 1, Kelvin Lai

More information

Management of HBV in KidneyTransplanted Patients Dr.E.Nemati

Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney

More information

Principles of Antiretroviral Therapy

Principles of Antiretroviral Therapy Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,

More information

Michael Healy August 8, 2012 Irving CRC Research Proposal. 1. Study Purpose and Rationale

Michael Healy August 8, 2012 Irving CRC Research Proposal. 1. Study Purpose and Rationale Michael Healy August 8, 2012 Irving CRC Research Proposal Prevalence of diarrhea and gastrointestinal infection in severely malnourished Human Immunodeficiency Virus (HIV) infected children in Durban,

More information

Outline. Epidemiology of Pediatric HIV 10/3/2012. I have no financial relationships with any commercial entity to disclose

Outline. Epidemiology of Pediatric HIV 10/3/2012. I have no financial relationships with any commercial entity to disclose Nutritional, Metabolic, and Gastrointestinal Complications in Pediatric HIV Infection Tracie L. Miller, MD Department of Pediatrics University of Miami, Miller School of Medicine I have no financial relationships

More information

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)

Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if

More information

Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi

Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting. Giovanni Guaraldi Frailty and age are independently associated with patterns of HIV antiretroviral use in a clinical setting Giovanni Guaraldi Potential conflicts of interest Research funding: Jansen, Gilead, MSD, BMS Consultancies:

More information

When to start: guidelines comparison

When to start: guidelines comparison The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count

More information

HIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship

HIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of

More information

Diabetes, Obesity and Heavy Proteinuria

Diabetes, Obesity and Heavy Proteinuria Diabetes, Obesity and Heavy Proteinuria Clinical Case 41 yo Black woman with heavy proteinuria History 2014: noted to have proteinuria on routine lab testing (1.1g/g). 1+ edema. Blood pressure has been

More information

Nephrology Grand Rounds. Mansi Mehta November 24, 2015

Nephrology Grand Rounds. Mansi Mehta November 24, 2015 Nephrology Grand Rounds Mansi Mehta November 24, 2015 Case 51yo F with PMH significant for Hypertension referred to renal clinic for evaluation of elevated Cr. no known history of CKD; baseline creatinine

More information

Mohammad Husain Department of Biotechnology, Jamia Millia Islamia New Delhi

Mohammad Husain Department of Biotechnology, Jamia Millia Islamia New Delhi Role of Vitamin D receptor (VDR) in HIV induced tubular injury Mohammad Husain Department of Biotechnology, Jamia Millia Islamia New Delhi 07/10/2015 INTRODUCTION Vitamin D is technically not a Vitamin;

More information

HIV/HCV co-infected patients should be prioritised for HCV treatment. Sanjay Bhagani Royal Free Hospital/UCL London

HIV/HCV co-infected patients should be prioritised for HCV treatment. Sanjay Bhagani Royal Free Hospital/UCL London HIV/HCV co-infected patients should be prioritised for HCV treatment Sanjay Bhagani Royal Free Hospital/UCL London Also requires other resources What should a prioritisation process Life-saving at this

More information

AGING KIDNEY IN HIV DISEASE

AGING KIDNEY IN HIV DISEASE AGING KIDNEY IN HIV DISEASE Michael G. Shlipak, MD, MPH Professor of Medicine, Epidemiology and Biostatistics, UCSF Chief, General Internal Medicine, San Francisco VA Medical Center Kidney, Aging and HIV

More information

Situación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona

Situación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona Situación actual de los pacientes VIH+ Esteban Martínez Hospital Clínic Barcelona Mortality per 1 patient-years HIV infection has changed from a fatal disease into a chronic condition This means long-term

More information

Kidney Disease in HIV. Kidney Disease in HIV: An Update for Ryan White Providers

Kidney Disease in HIV. Kidney Disease in HIV: An Update for Ryan White Providers Kidney Disease in HIV: An Update for Ryan White Providers Christina M. Wyatt, MD Assistant Professor Mount Sinai School of Medicine New York, New York FORMATTED: 11/16/2015 Learning Objectives After attending

More information

Future challenges for clinical care of an ageing population infected with HIV: a geriatric -HIV modelling study

Future challenges for clinical care of an ageing population infected with HIV: a geriatric -HIV modelling study Future challenges for clinical care of an ageing population infected with HIV: a geriatric -HIV modelling study Guaraldi G 1, De Francesco D 2, Malagoli A 1, Theou O 3, Zona S 1, Carli F 1, Dolci G 1,

More information

Medical Overview March 7, Nina Lambert, NP Inova Juniper Program

Medical Overview March 7, Nina Lambert, NP Inova Juniper Program Medical Overview March 7, 2019 Nina Lambert, NP Inova Juniper Program Nina.lambert@inova.org Inova Juniper Program Sites Offering medical care, case management and mental health for youth and adults who

More information

Elevated Serum Creatinine, a simplified approach

Elevated Serum Creatinine, a simplified approach Elevated Serum Creatinine, a simplified approach Primary Care Update Creighton University School of Medicine. April 27 th, 2018 Disclosure Slide I have no disclosures and have no conflicts with this presentation.

More information

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco

Immunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic

More information

HIV A 2017 Update Bill Rooney MD SCOR Global Life

HIV A 2017 Update Bill Rooney MD SCOR Global Life NHOLUA November 14, 2017 HIV A 2017 Update Bill Rooney MD SCOR Global Life Agenda 1 2 3 4 5 The Immune System HIV the illness Prevalence Diagnosis Natural Course Treatment A look at 100 HIV patients Changing

More information

Tenofovir Alafenamide (TAF)

Tenofovir Alafenamide (TAF) Frontier AIDS Education and Training Center Tenofovir Alafenamide (TAF) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, Frontier AETC ECHO January 28, 2016

More information

PART VI! IMPLICATIONS FOR THERAPIES

PART VI! IMPLICATIONS FOR THERAPIES PART VI! IMPLICATIONS FOR THERAPIES Background Current HIV and aging treatment advice: Start ART early and manage traditional risk factors for non-aids-related diseases aggressively Treatments to reverse

More information

HIV and transplant: obstacles and opportunities

HIV and transplant: obstacles and opportunities HIV and transplant: obstacles and opportunities Christine Durand, M.D. 18 de abril de 2013, XI Conferência Brasil Johns Hopkins University em HIV/AIDS Outline Part 1: Solid organ transplant (SOT) Part

More information

TOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY

TOXICITY, TOLERABILITY, AND ADHERENCE TO THERAPY SAFETY AND TOLERABILITY OF CURRENTLY AVAILABLE ANTIRETROVIRAL AGENTS * Esteban Martinez, MD, PhD ABSTRACT Safety and tolerability are important factors to consider when instituting or modifying therapy

More information

Anumber of clinical trials have demonstrated

Anumber of clinical trials have demonstrated IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines

More information

Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers

Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication. For Healthcare Providers Important Safety Information About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication For Healthcare Providers About TRUVADA for a PrEP Indication INDICATION AND PRESCRIBING CONSIDERATIONS TRUVADA,

More information

Tra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo. Cristina Gervasoni ASST FBF Sacco

Tra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo. Cristina Gervasoni ASST FBF Sacco Tra falsi miti e realtà Danno osseo e HIV: ciò che veramente conosciamo Cristina Gervasoni ASST FBF Sacco Outline What do I know? What do we know? What have we learned lately? Outline What do we know?

More information

TDF is particularly associated with loss of BMD

TDF is particularly associated with loss of BMD Earn 3 CPD Points online HIV infection and risk of fracture Key messages Antiretroviral therapy (ART) has increased the life expectancy of HIV-infected people, which can now match that of the uninfected

More information

Optimizing Health While Aging with HIV

Optimizing Health While Aging with HIV Slide 1 Optimizing Health While Aging with HIV Todd T. Brown, MD, PhD Division of Endocrinology and Metabolism Johns Hopkins University Unfortunately, We are Not Slide 2 Immortal But How Do We Want to

More information

Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP)

Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) Important Safety Information About Emtricitabine/Tenofovir Disoproxil Fumarate 200 mg/300 mg for HIV-1 Pre-exposure Prophylaxis (PrEP) For Healthcare Providers About Emtricitabine/Tenofovir Disoproxil

More information

50+ SHADES OF GREY, AGING WITH HIV

50+ SHADES OF GREY, AGING WITH HIV 50+ SHADES OF GREY, AGING WITH HIV R E B E C C A G L A S S M A N, M D I N S T R U C T O R O F M E D I C I N E, H A R V A R D M E D I C A L S C H O O L MR. C 71 years old Diagnosed with HIV in 1998 at the

More information

Antiretroviral Dosing in Renal Impairment

Antiretroviral Dosing in Renal Impairment Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis

More information

STRIBILD (aka. The Quad Pill)

STRIBILD (aka. The Quad Pill) NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared

More information

Safety Profile of Viread and Truvada. Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008

Safety Profile of Viread and Truvada. Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008 Safety Profile of Viread and Truvada Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008 Overview Safety assessment in drug development Physiology 101 Renal Bone Liver Safety profile

More information

For any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D,

For any cancer and for infection-related cancer, immediate ART was associated with a lower cancer risk in the first three models but not in models D, Immediate ART in START Cuts Risk of Infection-Linked Cancer About 75% Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston Mark Mascolini People who started antiretroviral

More information

Renal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir

Renal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir Original Article Vol. 29 No. 3 Renal safety of tenofovir:- Wiwattanathum P & Sungkanuparph S. 113 Renal safety of tenofovir in HIV-infected patients who switch from stavudine or zidovudine to tenofovir

More information

Attendees will be able to:

Attendees will be able to: A. Kay Kalousek, DO, MS, FACOFP kaysdroid@gmail.com April 21, 2017 Attendees will be able to: List strategies for prevention of HIV infection Explain the pharmacology of TDF/FTC related to PrEP Assess

More information

Natural history of HIV Infection

Natural history of HIV Infection HIV in Primary Care Joint RCGP/BHIVA Multidisciplinary Conference Dr Ian Williams University College London Medical School Friday 25 January 2013, Royal College of General Practitioners, London HIV Treatment

More information

HIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16

HIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16 HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be

More information

COPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017

COPD-Related Musculoskeletal Disease. Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 COPD-Related Musculoskeletal Disease Jessica Bon Field, MD, MS 2017 Update in Internal Medicine October 20, 2017 A 60-year old man with COPD comes into your office for a routine office visit. He is a former

More information

Report Back from CROI 2010

Report Back from CROI 2010 Report Back from CROI 2010 Conference on Retroviruses and Opportunistic Infections Edwin Charlebois, MPH PhD Associate Professor of Medicine Department of Medicine University of California, San Francisco

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Dr Paddy Mallon. Mater Misericordiae University Hospital, Dublin, Ireland. BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions

Dr Paddy Mallon. Mater Misericordiae University Hospital, Dublin, Ireland. BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions BHIVA AUTUMN CONFERENCE 2014 Including CHIVA Parallel Sessions Dr Paddy Mallon Mater Misericordiae University Hospital, Dublin, Ireland 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA

More information

Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN

Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets , Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN Emtricitabine / Tenofovir disoproxil Stada 200 mg/245 mg film-coated tablets 30.5.2016, Version 1.3 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a public summary Emtricitabine / Tenofovir

More information

HIV 101: Fundamentals of HIV Infection

HIV 101: Fundamentals of HIV Infection HIV 101: Fundamentals of HIV Infection David H. Spach, MD Professor of Medicine University of Washington Seattle, Washington Learning Objectives After attending this presentation, learners will be able

More information

2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?

2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen? Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is

More information

Mild and Severe Adverse Effects of Antiretroviral Treatment

Mild and Severe Adverse Effects of Antiretroviral Treatment Mild and Severe Adverse Effects of Antiretroviral Treatment Gordon Dickinson, MD Professor of Medicine and Chief, Infectious Diseases, Miller School of Medicine, University of Miami Abacavir, available

More information

Vemlidy. (tenofovir alafenamide) New Product Slideshow

Vemlidy. (tenofovir alafenamide) New Product Slideshow Vemlidy (tenofovir alafenamide) New Product Slideshow Introduction Brand name: Vemlidy Generic name: Tenofovir alafenamide Pharmacological class: Nucleoside analogue (reverse transcriptase inhibitor) Strength

More information

Odefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow

Odefsey. (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Odefsey (emtricitabine, rilpivirine, tenofovir alafenamide) New Product Slideshow Introduction Brand name: Odefsey Generic name: Emtricitabine, rilpivirine, tenofovir alafenamide (TAF) Pharmacological

More information

EU-Risk Management Plan for Emtricitabine/Tenofovir (NL/H/3635/001/DC and NL/H/3636/001/DC) V1.3

EU-Risk Management Plan for Emtricitabine/Tenofovir (NL/H/3635/001/DC and NL/H/3636/001/DC) V1.3 VI.2 Elements for a public summary 200 mg/245 mg film-coated tablets VI.2.1 Overview of disease epidemiology HIV-1 infection In this decade, the global prevalence of HIV-1 infection stabilized

More information

Alterations of Renal and Urinary Tract Function

Alterations of Renal and Urinary Tract Function Alterations of Renal and Urinary Tract Function Chapter 29 Urinary Tract Obstruction Urinary tract obstruction is an interference with the flow of urine at any site along the urinary tract The obstruction

More information

Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update

Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,

More information

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini

First line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /

More information

Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT

Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT The Kidney in Multiple Myeloma Tarek ElBaz, MD. Prof. Internal Medicine Chief, Division of Renal Medicine Al Azhar University President, ESNT Normal Cell Plasma cells produce antibodies that bind to antigens,

More information

The impact of antiretroviral drugs on Cardiovascular Health

The impact of antiretroviral drugs on Cardiovascular Health The impact of antiretroviral drugs on Cardiovascular Health José López-Sendón Hospital Universitario La Paz. IdiPaz Madrid. Spain Research grants and honoraria from (research committees, clinical trials,

More information

Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS

Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS MICHELLE A. RUDEK, PHARM.D., PH.D. ASSOCIATE PROFESSOR OF ONCOLOGY AND MEDICINE JOHNS HOPKINS UNIVERSITY Disclosures Spouse Employed Novavax

More information

Clinical syndromes: experience from the bedside. Professor Rob Miller University College Hospital, London

Clinical syndromes: experience from the bedside. Professor Rob Miller University College Hospital, London Clinical syndromes: experience from the bedside Professor Rob Miller University College Hospital, London Presented at ECCMID Berlin April 30 th 2013 Pneumocystis jirovecii pneumonia http://commons.wikimedia.org/wiki/file

More information

Paul Volberding, M.D. (Chair) Igor Grant, M.D., FRCP John G. Bartlett, M.D. H. Clifford Lane, M.D. Celia Maxwell, M.D., FACP Carlos del Rio, M.D.

Paul Volberding, M.D. (Chair) Igor Grant, M.D., FRCP John G. Bartlett, M.D. H. Clifford Lane, M.D. Celia Maxwell, M.D., FACP Carlos del Rio, M.D. HIV and Disability Committee membership Paul Volberding, M.D. (Chair) San Francisco VA Medical Center John G. Bartlett, M.D. Johns Hopkins University Carlos del Rio, M.D. Emory University Patricia M. Flynn,

More information

Metabolic complications of HIV and HAART: The hyperlactataemia syndromes

Metabolic complications of HIV and HAART: The hyperlactataemia syndromes Metabolic complications of HIV and HAART: The hyperlactataemia syndromes Colin Menezes Division of Infectious Diseases Department of Internal Medicine Chris Hani Baragwanath Academic Hospital University

More information

Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord

Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Mortalité et Morbidité à l ère des traitements antirétroviraux dans les Pays du Nord Laurence WEISS Hôpital Européen Georges Pompidou, Université Paris-Descartes Paris, France Deaths per 100 Person-Years

More information

The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV

The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV The Association Between Comorbidities and Neurocognitive Impairment in Aging Veterans with HIV Arianna Perra, P syd, Moira Dux, PhD Terry Lee- Wilk, PhD HIV and HCV in the VA VA is the largest provider

More information

Simplifying HIV Treatment Now and in the Future

Simplifying HIV Treatment Now and in the Future Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line

More information

Aging and HIV: Living Life with Silver Hair

Aging and HIV: Living Life with Silver Hair Georgia Southern University Digital Commons@Georgia Southern 6th Annual Rural HIV Research and Training Conference Sep 21st, 4:30 PM - 5:15 PM Aging and HIV: Living Life with Silver Hair Barbara J. Blake

More information

Hepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019

Hepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019 Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral

More information

Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.

Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H. Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for

More information